Skip to main content
. 2018 May 31;16(2):1758–1764. doi: 10.3892/ol.2018.8852

Figure 1.

Figure 1.

Knockdown of ZEB1 and ZEB2 in mouse glioma cells. (A) After transfection of mouse glioma GL261 cells with control siRNA (NC) or three different kinds of siRNAs targeting mouse ZEB1 (i-iii) or ZEB2 (i-iii), expression of ZEBs was examined at the protein level by immunoblot analysis. (−) indicates no transfection. (B-D) GL261 cells without transfection (−), transfected with control siRNA (NC), or transfected with siRNAs against both ZEB1 (i) and ZEB2 (iii) or either alone were subjected to immunoblot analysis using a stripping and reblotting procedure (B), (C) MTT assay with one-way factorial ANOVA followed by Fisher's PLSD test (n.s, not significant), and (D) Boyden chamber assay with one-way factorial ANOVA followed by Fisher's PLSD test (**P<0.01). Each value represents the mean ± sd. of triplicate determinations from a representative experiment. (C and D) Similar results were obtained in at least two independent experiments. (E) At 12 h after transfection with siRNAs, BALB/cAJcl nude mice were implanted with GL261 cells pretransfected with control siRNA (NC) or both ZEB1 (i) and ZEB2 (ii) siRNAs. The mice were reared for 90 days, followed by Kaplan-Meier survival analysis (n=7).